EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options

EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options

User Photo
EMJ

5 years
669 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients symptom burden and helped them feel better. Presented by Ruben Mesa, MD, FACP, Mayo Clinic, Scottsdale, AZ, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay